BeiGene Announces Acceptance of a Supplemental New Drug Application in China for REVLIMID® in Relapsed or Refractory Indolent LymphomaGlobeNewsWire • 12/22/19
BeiGene Announces Results of Phase 3 ASPEN Trial of Zanubrutinib Compared to Ibrutinib for the Treatment of Patients with Waldenström’s MacroglobulinemiaGlobeNewsWire • 12/16/19
BeiGene Announces Clinical Data on Investigational Anti-PD-1 Antibody Tislelizumab in Combination with Sitravatinib at European Society for Medical Oncology Immuno-Oncology (ESMO I-O) Congress 2019GlobeNewsWire • 12/13/19
BeiGene Announces Clinical Data on BRUKINSA™ (Zanubrutinib) at the 61st American Society of Hematology (ASH) Annual MeetingGlobeNewsWire • 12/08/19
BeiGene Announces Clinical Data on Tislelizumab Presented at European Society for Medical Oncology (ESMO) Asia 2019 CongressGlobeNewsWire • 11/23/19
U.S. FDA Grants BeiGene’s BRUKINSA™ (zanubrutinib) Accelerated Approval to Treat Adult Patients with Mantle Cell Lymphoma Who Received at Least One Prior TherapyGlobeNewsWire • 11/14/19
Amgen Is Taking A $2.7 Billion Stake In A Chinese Biotech — Here's WhyInvestors Business Daily • 10/31/19
BeiGene Announces Clinical Data on Tislelizumab and Pamiparib Presented at the European Society for Medical Oncology (ESMO) Congress 2019GlobeNewsWire • 09/30/19
BeiGene Announces Clinical Data on Tislelizumab and Pamiparib to Be Presented at the European Society for Medical Oncology (ESMO) Congress 2019GlobeNewsWire • 09/26/19
BeiGene Announces Clinical Results on Tislelizumab Presented at the 22nd Annual Meeting of the Chinese Society of Clinical Oncology (CSCO)GlobeNewsWire • 09/22/19
BeiGene Announces Clinical Data to Be Presented at the Annual Meeting of the Chinese Society of Clinical Oncology (CSCO)GlobeNewsWire • 09/11/19
BeiGene to Present at the Morgan Stanley 17th Annual Global Healthcare ConferenceGlobeNewsWire • 09/03/19
BeiGene Announces U.S. FDA Acceptance and Grant of Priority Review for its New Drug Application of Zanubrutinib in Patients with Relapsed/Refractory Mantle Cell LymphomaGlobeNewsWire • 08/21/19